Safety and Immunogenicity Following Meningococcal and Pneumococcal Immunization Among Adult People Living With HIV
Safety and Immunogenicity Following Meningococcal and Pneumococcal Immunization Among Adult People Living With HIV: A Single Center, Non-blinded, Randomized Clinical Trial
Thomas Benfield
55 participants
Apr 28, 2021
INTERVENTIONAL
Conditions
Summary
MENPI is an investigator-initiated single-centre randomized controlled trial which aims to assess the efficacy and safety of meningococcal and pneumococcal vaccination in adults living with HIV receiving antiretroviral treatment. Participants are randomized 1:1 to either a two-dose Menveo® and Bexsero® regimen or a Prevenar13®/Pneumovax23® prime-boost regimen at day 0 and day 60 and cross over on day 90. All participants will follow an identical follow up program including plasma collection, pharyngeal swab, and adverse event registration. Immunogenicity will be determined on venous blood sampled at 30 days post-vaccination and yearly for five years.
Eligibility
Inclusion Criteria5
- Age ≥ 18 years
- Seropositive for HIV-1
- Recipient of ART
- Plasma HIV-RNA \< 500 copies/ml
- Patients written consent obtained
Exclusion Criteria12
- Pregnancy or breastfeeding
- History of meningococcal or pneumococcal vaccination
- Allergies towards any of the vaccine components
- Temperature \> 38 ᵒC
- Sign of bacterial infection
- Previous known or suspected disease caused by N. meningitidis
- Active AIDS associated illness
- Active malignancy
- End-stage renal or liver disease
- Bleeding disorder
- Recipient of any blood, blood products and/or plasma derivatives or any parenteral immunoglobulin preparation within the last month
- Use of immunosuppressive agents (corticosteroids, cancer chemotherapeutic agents etc.)
Interventions
One dose (0.5 ml) of conjugate vaccine against meningococcal serogroups ACWY (Menveo®) and one dose of a recombinant protein-based vaccine against meningococcal serogroup B (Bexsero®) at day 0 followed by another dose (0.5 ml) of each vaccine at day 60.
One dose (0.5 ml) of pneumococcal conjugate vaccine (Prevenar13®) at day 0 and one dose (0.5 ml) of pneumococcal polysaccharide vaccine (Pneumovax23®) at day 60.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04875819